Veracyte(NASDAQ) VCYT

Current Price$57.85

Market Cap$4.63B

Since IPO (2013)+338%

5 Year+47%

1 Year+139%

1 Month+8%

Veracyte last closing stock price
Metric	Price	Date
Last close	USD 57.88	2026-07-23

Veracyte stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.26%	USD 59.22	2026-07-16
1 month	+7.6%	USD 53.79	2026-06-23
3 month	+68.6%	USD 34.33	2026-04-24
Year to date	+37.48%	USD 42.10	2025-12-31
1 year	+139.07%	USD 24.21	2025-07-23
3 year	+110.17%	USD 27.54	2023-07-24
5 year	+47.46%	USD 39.25	2021-07-23
Since inception	+337.81%	USD 13.25	2013-10-30

Veracyte Financials at a Glance

Market Cap

$4.63B

Revenue (TTM)

$541.74M

Net Income (TTM)

$88.01M

EPS (TTM)

$1.09

P/E Ratio

53.40

Dividend

$0.00

Beta (Volatility)

1.89 (High)

Dividend

$0.00

Beta (Volatility)

1.89 (High)

Price

$57.85

Volume

16,128

Open

$57.70

Price

$57.85

Volume

16,128

Open

$57.70

Previous Close

$57.85

Daily Range

$57.40 - $59.10

52-Week Range

$22.92 - $60.91

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

1.89 (High)

Price

$57.85

Volume

16,128

Open

$57.70

Previous Close

$57.85

Daily Range

$57.40 - $59.10

52-Week Range

$22.92 - $60.91

Estimated Earnings Date

Jul 30, 2026

VCYT News

A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Robert IzquierdoJul 4, 2026

Here's Why This Little-Known Growth Stock Is a Buy

Kody KesterMay 22, 2023

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?

Kody KesterMar 10, 2023

Page 1

VCYT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Veracyte

Veracyte helps doctors and patients make better choices about cancer. Their tests check for cancer in the prostate, thyroid, and lungs. These tests help people avoid surgery they do not really need.

How the Company Guides Care

Prostate and Thyroid Tests: Centralized laboratory services for Decipher and Afirma brands used to confirm if tumors are aggressive; accounts for 97% of revenue.
Breast Cancer Assay: Prosigna tests sold as kits to international hospitals for local use; accounts for roughly 3% of revenue.
Lung and Bladder Classifiers: Advanced genomic tests that identify risk and guide treatment decisions; included in the testing revenue segment.

Moving into New Markets

Acquired C2i to build the TrueMRD platform, which monitors for minimal residual disease to see if cancer returns after treatment.
Ended control of Veracyte SAS in August 2025, which stopped the company's contract manufacturing and biopharmaceutical work in France.
Filed a patent infringement lawsuit against Sonic Healthcare USA in May 2025 regarding molecular testing for thyroid nodules.
Planned a 2026 launch for the Prosigna test as a laboratory developed test, which are tests performed in the company's own labs.

Global Reach and Local Labs

The company operates high-tech laboratories in California and Texas to process complex samples from across the United States. It also sells test kits globally, allowing international hospitals to provide advanced results without shipping patient samples overseas.

A Strong Financial Trajectory

Total revenue reached $139.1 million in Q1 2026, up 21.5% from $114.5 million in Q1 2025.
Net income rose to $28.7 million in Q1 2026, up 307.4% year-over-year.
Free cash flow hit $32.3 million in Q1 2026, up from $3.5 million in Q1 2025.
Operating cash flow grew to $35.2 million in Q1 2026, up 556.8% from $5.4 million in Q1 2025.

Bottom Line

Veracyte has transitioned into a profitable organization focused on high-value genomic diagnostics. Its strategy relies on centralized lab testing and international kit sales to support long-term growth across multiple cancer types.

AI Generated • May 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

755

CEO

Marc A. Stapley

Website

www.veracyte.com

Headquarters

South San Francisco, CA 94080, US

VCYT Financials

Key Financial Metrics (TTM)

Gross Margin

71.31%

Operating Margin

12.45%

Net Income Margin

16.25%

Return on Equity

6.86%

Return on Capital

5.50%

Return on Assets

6.13%

Earnings Yield

1.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.63B

Shares Outstanding

79.79M

Volume

16.13K

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

$386.31M

Operating Income

$67.46M

EBITDA

$112.23M

Operating Cash Flow

$166.16M

Capital Expenditure

-$11.35M

Free Cash Flow

$154.81M

Cash & ST Invst.

$439.06M

Total Debt

$39.33M

Veracyte Performance Analysis

Veracyte annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 296,536,000	35.1%
2023	2023-12-31	USD 361,051,000	21.8%
2024	2024-12-31	USD 445,764,000	23.5%
2025	2025-12-31	USD 517,145,000	16.0%

Veracyte sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	13.7%
Q3	2025-09-30	1.3%
Q4	2025-12-31	6.6%
Q1	2026-03-31	-1.1%

Veracyte annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.51	-54.1%
2023	2023-12-31	USD -1.02	100.4%
2024	2024-12-31	USD 0.31	N/A
2025	2025-12-31	USD 0.82	166.7%

Veracyte sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-114.2%
Q3	2025-09-30	2020.0%
Q4	2025-12-31	108.3%
Q1	2026-03-31	-30.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$139.07M

+21.5%

Gross Profit

$100.58M

+26.5%

Gross Margin

72.32%

N/A

Market Cap

$4.63B

N/A

Market Cap/Employee

$6.13M

N/A

Employees

755

N/A

Net Income

$28.71M

+307.4%

EBITDA

$35.40M

+442.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$439.06M

+52.8%

Total Debt

$39.33M

-22.1%

Accounts Receivable

$50.11M

-6.8%

Inventory

$21.42M

-11.7%

Long Term Debt

$34.99M

-18.8%

Short Term Debt

$4.35M

-41.3%

Return on Assets

6.13%

N/A

Return on Invested Capital

4.89%

N/A

Free Cash Flow

$32.25M

+810.3%

Operating Cash Flow

$35.22M

+556.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FOLDAmicus Therapeutics, Inc.

FOLDAmicus Therapeutics, Inc.$14.49+0.00%

KNSAKiniksa Pharmaceuticals International, plc

KNSAKiniksa Pharmaceuticals International, plc$63.05+0.98%

LEGNLegend Biotech Corporation

LEGNLegend Biotech Corporation$23.53+0.00%

APLSApellis Pharmaceuticals, Inc.

APLSApellis Pharmaceuticals, Inc.$41.03+0.00%

ADPTAdaptive Biotechnologies Corporation

ADPTAdaptive Biotechnologies Corporation$22.31+1.64%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$36.23+3.51%

SRRKScholar Rock Holding Corporation

SRRKScholar Rock Holding Corporation$49.48+2.44%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.76-0.29%

NOKNokia

NOKNokia$9.73-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.56-0.08%

TAT&T

TAT&T$22.96-0.00%

SMCISuper Micro Computer

SMCISuper Micro Computer$31.20+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$66.30-0.06%

SOFISoFi Technologies

SOFISoFi Technologies$16.65-0.02%

Questions About VCYT

What is the current price of Veracyte?

Veracyte is trading at $57.85 per share.

What is the 52-week range for Veracyte?

Over the past 52 weeks, Veracyte has traded between $22.92 and $60.91.

How much debt does Veracyte have?

As of the most recent reporting period, Veracyte reported total debt of $39.33M.

How much cash does Veracyte have on hand?

Veracyte reported $263.14M in cash and cash equivalents in its most recent financial results.

What is Veracyte’s dividend yield?

Veracyte does not currently have a dividend yield.

Veracyte(NASDAQ) VCYT

Veracyte Financials at a Glance

VCYT News

5 Best Biotech ETFs for 2026 and How to Invest

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte (VCYT) Q2 Revenue Jumps 14%

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?

Here's Why This Little-Known Growth Stock Is a Buy

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?

VCYT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Veracyte

How the Company Guides Care

Moving into New Markets

Global Reach and Local Labs

A Strong Financial Trajectory

Bottom Line

VCYT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Veracyte Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VCYT

What is the current price of Veracyte?

What is the 52-week range for Veracyte?

How much debt does Veracyte have?

How much cash does Veracyte have on hand?

What is Veracyte’s dividend yield?

Premium Investing Services